🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 107 of 116

  1. Tarlatamab

    Amgen

    Neuroendocrine Prostate Cancer

    phase 1 small molecule completed

    1 trial

  2. Tarlatamab

    BEONE MEDICINES AUS PTY LTD

    Extensive Stage Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  3. Tcrx T cell

    TScan Therapeutics

    Gastric Cancer

    phase 1 mab active

    1 trial

  4. Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)

    phase 1 small molecule active

    1 trial

  5. Tepotinib

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  6. The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)

    Sinobioway Cell Therapy Co.,

    Lymphoma

    phase 1 mab active

    1 trial

  7. The detection of tumor-associated fibrosis in colorectal peritoneal metastases by FAPI-PET (TROMPET)

    Disc Medicine

    Metastatic colorectal cancer

    phase 1 other active

    1 trial

  8. The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory B-cell Lymphoma

    phase 1 other active

    1 trial

  9. This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  10. This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  11. ThisCART19A

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  12. ThisCART7 cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  13. Tipifarnib

    Kura Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  14. Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE

    Hoffmann-La Roche

    Urothelial carcinoma (UC)

    phase 1 small molecule active

    1 trial

  15. To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents after single dose administration and to assess BE of a regular strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents at steady state in men with prostate cancer

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 1 other active

    1 trial

  16. Trastuzumab

    Hoffmann-La Roche

    Early Breast Cancer

    phase 1 small molecule completed

    1 trial

  17. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  18. Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

    Daiichi Sankyo

    Locally advanced/metastatic breast or non-small cell lung cancer

    phase 1 other active

    1 trial

  19. Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs).

    The George Institute

    advanced or metastasic triple-negative breast cancer

    phase 1 other active

    1 trial

  20. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  21. Trebananib 3 mg/kg

    Takeda

    Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  22. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  23. Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors

    Genmab A/S

    Advanced Malignant Solid Tumors

    phase 1 other active

    1 trial

  24. Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors

    Genmab A/S

    Metastatic or advanced malignant solid tumors

    phase 1 other active

    1 trial

  25. Triprorelin for injection

    The First People's Hospital of Lianyungang

    Prostate Cancer (CRPC)

    phase 1 small molecule active

    1 trial

  26. Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  27. Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

    Merck Sharp and Dohme

    Metastatic or Locally Advanced Unresectable Solid Tumors

    phase 1 other active

    1 trial

  28. U96

    The First People's Hospital of Lianyungang

    Relapsed or Refractory B Cell Leukemia and Lymphoma

    phase 1 small molecule active

    1 trial

  29. UB-921

    United Therapeutics Europe Ltd

    Breast Neoplasm

    phase 1 mab completed

    1 trial

  30. UTAA09 injection

    The First People's Hospital of Lianyungang

    Recurrent or Refractory B-cell Non Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  31. Ublituximab + TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  32. Unesbulin

    PTC THERAPEUTICS, INC.

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  33. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 1 small molecule completed

    1 trial

  34. VIR-5500

    Vir Biotechnology

    Hormone-refractory Prostate Cancer

    phase 1 small molecule active

    1 trial

  35. VIR-5525

    Vir Biotechnology

    Solid Tumor Malignancies

    phase 1 small molecule active

    1 trial

  36. VX15/2503

    VACCINEX, INC.

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  37. VX15/2503

    VACCINEX, INC.

    Squamous Cell Carcinoma of the Head and Neck

    phase 1 mab active

    1 trial

  38. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  39. Vantictumab

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  40. Vantictumab combined with paclitaxel

    Mereo BioPharma Group plc

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

  41. Vemurafenib Oral Tablet [Zelboraf]

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

    phase 1 small molecule active

    1 trial

  42. Venetoclax

    Kura Oncology

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  43. Venetoclax

    Karyopharm Therapeutics Inc

    Acute Leukemia of Ambiguous Lineage in Relapse

    phase 1 small molecule active

    1 trial

  44. Venetoclax

    Karyopharm Therapeutics Inc

    Diffuse Large B-cell Lymphoma

    phase 1 small molecule completed

    1 trial

  45. Vitamin B6-restricted diet + immunotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor Cancer

    phase 1 other active

    1 trial

  46. Volasertib, low dose, d1q3w

    Boehringer Ingelheim

    Neoplasms

    phase 1 small molecule completed

    1 trial

  47. Vyxeos

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  48. WGc-0201 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 1 mab active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.